MD102

Overview

MD102 is an orally active transglutaminase 2 (TG2) inhibitor with an IC 50 of 0.35 μM. MD102 binds to the β-sandwich domain of TG2, disrupts the interaction between TG2 and p53 , stabilizes p53, and reduces the activity of p-AKT and p-mTOR signaling pathways. MD102 induces cell apoptosis and inhibits tumor growth. MD102 can be used for the research of renal cell carcinoma.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Renal Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Glutaminase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Akt

Product Information

• Catalog No.: HY-162141
• CAS No.: 2755794-94-4
• Molecular Formula: C13H4BrCl2FN2O2
• Molecular Weight: 389.99
• Purity: 98.01%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source